IRCCS CANDIOLO Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2017
NCT02850419
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Candiolo Cancer Institute - IRCCS | FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS CANDIOLO

Active Ingredients

Drugs in Phase 2 Trials (1)

doxorubicin (Doxil) (1 trial)

Drugs in Phase 1 Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Peritoneal Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2